durvalumab,tremelimumab
astrazeneca,pfizer
['poseidon']
today melissa johnson presented the 4 year follow up of the #poseidon trial, important results because the most relevant achievement w/ io is long term survival, and the combo d+t+chemo suggests the biggest long term benefit, particularly in mkras pts. #esmo2022 #esmo22 
Medical Oncologist and Clinical Researcher (lung & MPM) Head of the Thoracic Oncology Clinic at INER México City, Private practice ABC Medical Center Santa Fe